Biogen Inc. (BIIB) NASDAQ

183.78

+0.45(+0.25%)

Updated at April 01 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Christopher A. Viehbacher	President, Chief Executive Officer & Director	6.15M	1960
Ginger Gregory	Executive VP & Chief Human Resources Officer	1.59M	1968
Nicole Murphy	Executive VP and Head of Pharmaceutical Operations & Technology	1.86M	1973
Priya Singhal	Executive VP & Head of Development	1.95M	1969
Susan H. Alexander	Executive VP & Chief Legal Officer	2.63M	1957
Adam Keeney	Executive VP & Head of Corporate Development	0	1977
Guy Hadari	Chief Information Officer	0	N/A
Sean Godbout	Chief Accounting Officer & Global Corporate Controller	0	N/A
Tim Power	Head of Investor Relations	0	N/A
Robin C. Kramer	Executive VP & CFO	0	1966

Name

Title

Pay

Year Born

Christopher A. Viehbacher

President, Chief Executive Officer & Director

6.15M

1960

Ginger Gregory

Executive VP & Chief Human Resources Officer

1.59M

1968

Nicole Murphy

Executive VP and Head of Pharmaceutical Operations & Technology

1.86M

1973

Priya Singhal

Executive VP & Head of Development

1.95M

1969

Susan H. Alexander

Executive VP & Chief Legal Officer

2.63M

1957

Adam Keeney

Executive VP & Head of Corporate Development

1977

Guy Hadari

Chief Information Officer

N/A

Sean Godbout

Chief Accounting Officer & Global Corporate Controller

N/A

Tim Power

Head of Investor Relations

N/A

Robin C. Kramer

Executive VP & CFO

1966

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.